Targacept, AstraZeneca Face Another Failure With NNR Class
This article was originally published in Pharmaceutical Approvals Monthly
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.
You may also be interested in...
Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.
After receiving disappointing news about one of its Phase 2 NNR drugs, Targacept waits to hear from its partner, AZ